Cargando…
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2
Loss of function of the neurofibromatosis type 2 (NF2) tumor suppressor gene leads to the formation of schwannomas, meningiomas, and ependymomas, comprising ∼50% of all sporadic cases of primary nervous system tumors. NF2 syndrome is an autosomal dominant condition, with bi-allelic inactivation of g...
Autores principales: | Prabhakar, Shilpa, Beauchamp, Roberta L., Cheah, Pike See, Yoshinaga, Akiko, Haidar, Edwina Abou, Lule, Sevda, Mani, Gayathri, Maalouf, Katia, Stemmer-Rachamimov, Anat, Jung, David H., Welling, D. Bradley, Giovannini, Marco, Plotkin, Scott R., Maguire, Casey A., Ramesh, Vijaya, Breakefield, Xandra O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263409/ https://www.ncbi.nlm.nih.gov/pubmed/35846573 http://dx.doi.org/10.1016/j.omtm.2022.06.012 |
Ejemplares similares
-
AAV9 transduction mediated by systemic delivery of vector via retro-orbital injection in newborn, neonatal and juvenile mice
por: Prabhakar, Shilpa, et al.
Publicado: (2021) -
Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas
por: Kukutla, Phanidhar, et al.
Publicado: (2021) -
Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin
por: Cheah, Pike-See, et al.
Publicado: (2021) -
Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1
por: Prabhakar, Shilpa, et al.
Publicado: (2019) -
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2
por: Jordan, Justin T, et al.
Publicado: (2023)